Current Cancer Therapy Reviews

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back Subscribe
Case Report

Uncommon Metachronicity: Breast and Endometrial Carcinomas in a Young Woman with No Familial Cancer History - A Case Report

Author(s): Naina Kumar*, Seetu Palo, Aadil Sinha and Mishu Mangla

Volume 21, Issue 3, 2025

Published on: 23 February, 2024

Page: [427 - 432] Pages: 6

DOI: 10.2174/0115733947283731240215102133

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Background: Worldwide, breast and endometrial carcinomas are the two most common cancers of women, but their coexistence in a woman <40 years of age is a rare event. The risk of developing a new second primary cancer is higher in cancer survivors compared to those without a history of cancer. The exact pathogenesis of two different primary malignancies is not clear. Still, the coexistence of breast and endometrial carcinoma may be due to germline mutations of p53, BRCA 1, and BRCA 2 genes, environmental, hereditary, and immune-mediated factors.

Case Presentation: The present case report briefs the finding of a 37-year-old woman who presented to the Gynecological outpatient department with complaints of abnormal uterine bleeding and a solid irregular lump in the upper outer quadrant of the right breast and the right axilla. She had a history of modified radical mastectomy for left breast ductal carcinoma five years back. She was diagnosed as a case of metachronous endometrial carcinoma (stage IA) with a recurrence of invasive ductal carcinoma in the right breast with metastasis to the right axillary lymph node.

Conclusion: The metachronous development of breast and endometrial carcinoma in young women is relatively rare. In young patients <40 years of age with gynecological or breast carcinoma, a thorough work-up, including genetic testing and follow-up, should be done for early diagnosis of metachronous or synchronous primary malignancies of other organs.

Keywords: Breast carcinoma, endometrial carcinoma, malignancy, metachronous tumors, synchronous tumors, MRM.

« Previous

Graphical Abstract

[1]
Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020. Cancer Commun 2021; 41(11): 1183-94.
[http://dx.doi.org/10.1002/cac2.12207] [PMID: 34399040]
[2]
Cancer Stat Facts. Uterine Cancer. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Available from: https://seer.cancer.gov/statfacts/html/corp.html
[3]
Banimostafavi ES, Tayebi S, Tayebi M, Montazer F. Case Report: Synchronous primary malignancy including the breast and endometrium. F1000 Res 2017; 6: 1502.
[http://dx.doi.org/10.12688/f1000research.11971.1] [PMID: 29333235]
[4]
Choi S, Lee YJ, Jeong JH, et al. Risk of endometrial cancer and frequencies of invasive endometrial procedures in young breast cancer survivors treated with tamoxifen: A nationwide study. Front Oncol 2021; 11: 636378.
[http://dx.doi.org/10.3389/fonc.2021.636378] [PMID: 34150613]
[5]
Sun C, Chen G, Yang Z, et al. Safety of ovarian preservation in young patients with early-stage endometrial cancer: A retrospective study and meta-analysis. Fertil Steril 2013; 100(3): 782-787.e5.
[http://dx.doi.org/10.1016/j.fertnstert.2013.05.032] [PMID: 23830105]
[6]
Satei J, Afrakhteh AN, Aldecoa KAT. Endometrial adenocarcinoma in young women: A case report and review of literature. Cureus 2023; 15(9): e45287.
[http://dx.doi.org/10.7759/cureus.45287] [PMID: 37846282]
[7]
Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 2008; 100(22): 1643-8.
[http://dx.doi.org/10.1093/jnci/djn344] [PMID: 19001605]
[8]
Erić I, Petek Erić A, Kristek J, Koprivčić I, Babić M. Breast cancer in young women: Pathologic and immunohistochemical features. Acta Clin Croat 2018; 57(3): 497-502.
[http://dx.doi.org/10.20471/acc.2018.57.03.13] [PMID: 31168183]
[9]
Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012; 131(3): 1061-6.
[http://dx.doi.org/10.1007/s10549-011-1872-9] [PMID: 22080245]
[10]
Lee HB, Han W. Unique features of young age breast cancer and its management. J Breast Cancer 2014; 17(4): 301-7.
[http://dx.doi.org/10.4048/jbc.2014.17.4.301] [PMID: 25548576]
[11]
Grzankowski KS, Szender JB, Spring-Robinson CL, Lele SB, Odunsi KO, Frederick PJ. Evaluation of metachronous breast and endometrial cancers: Preroutine and postroutine adjuvant tamoxifen use. Int J Gynecol Cancer 2016; 26(8): 1440-7.
[http://dx.doi.org/10.1097/IGC.0000000000000785] [PMID: 27648713]
[12]
Martin-Dunlap TM, Wachtel MS, Margenthaler JA. Outcomes for patients who are diagnosed with breast and endometrial cancer. Oncol Lett 2013; 6(4): 1103-7.
[http://dx.doi.org/10.3892/ol.2013.1491] [PMID: 24137471]
[13]
Derwinger K, Gustavsson B. A study of aspects on gender and prognosis in synchronous colorectal cancer. Clin Med Insights Oncol 2011; 5: CMO.S7871.
[http://dx.doi.org/10.4137/CMO.S7871] [PMID: 21912492]
[14]
Aydiner A, Karadeniz A, Uygun K, et al. Multiple primary neoplasms at a single institution: Differences between synchronous and metachronous neoplasms. Am J Clin Oncol 2000; 23(4): 364-70.
[http://dx.doi.org/10.1097/00000421-200008000-00011] [PMID: 10955865]
[15]
Pan SY, Huang CP, Chen WC. Synchronous/metachronous multiple primary malignancies: Review of associated risk factors. Diagnostics 2022; 12(8): 1940.
[http://dx.doi.org/10.3390/diagnostics12081940] [PMID: 36010291]
[16]
Tziris N, Dokmetzioglou J, Giannoulis K, et al. Synchronous and metachronous adenocarcinomas of the large intestine. Hippokratia 2008; 12(3): 150-2.
[PMID: 18923668]
[17]
Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97(19): 1428-37.
[http://dx.doi.org/10.1093/jnci/dji290] [PMID: 16204692]
[18]
Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: From a phenotypical to a molecular-based classification. Virchows Arch 2004; 444(3): 213-23.
[http://dx.doi.org/10.1007/s00428-003-0947-3] [PMID: 14747944]
[19]
Ferriss JS, Erickson BK, Shih IM, Fader AN. Uterine serous carcinoma: Key advances and novel treatment approaches. Int J Gynecol Cancer 2021; 31(8): 1165-74.
[http://dx.doi.org/10.1136/ijgc-2021-002753] [PMID: 34210768]
[20]
Li G, Yao J, Wu T, et al. Triple metachronous primary cancer of uterus, colon, and breast cancer. Medicine 2020; 99(34): e21764.
[http://dx.doi.org/10.1097/MD.0000000000021764] [PMID: 32846803]
[21]
Alam M, Perween R, Siddiqui S. Triple malignancy involving breast, ovary, and uterine vault: A case report and literature review. J Cancer Res Ther 2017; 13(6): 1059-61.
[http://dx.doi.org/10.4103/0973-1482.220419] [PMID: 29237978]
[22]
Lee E, Ji YI. A case of uterine carcinosarcoma detected simultaneously with breast and colon cancer (triple primary malignant tumor). Case Rep Oncol 2018; 11(2): 431-5.
[http://dx.doi.org/10.1159/000489844] [PMID: 30057538]
[23]
Vogt A, Schmid S, Heinimann K, et al. Multiple primary tumours: Challenges and approaches, a review. ESMO Open 2017; 2(2): e000172.
[http://dx.doi.org/10.1136/esmoopen-2017-000172] [PMID: 28761745]
[24]
Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. PET Clin 2018; 13(3): 339-54.
[http://dx.doi.org/10.1016/j.cpet.2018.02.006] [PMID: 30100074]
[25]
PDQ Adult Treatment Editorial Board. Endometrial Cancer Treatment (PDQ®): Health Professional Version. 2023 Mar 13. In: PDQ cancer information summaries [Internet]. Bethesda (MD): National cancer institute. 2002. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65829/

Rights & Permissions Print Cite